MacroGenics | MGNX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Genmab DKK 748M 77M 2026-06
Geron USD 52.07M 6.73M 2026-03
Gilead Sciences USD 3.95B 19.57B 2026-06
J&J USD 17.83B 388M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Xencor USD 87.82M 5.44M 2026-06